Emergent BioSolutions
EBS
$3.27
Share price
3.15%
Change (1 day)
-89.36%
Change (1 year)
Categories
P/S ratio for Emergent BioSolutions (EBS)
P/S ratio as of September 2023 (TTM): 0.1578
According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.15778. At the end of 2023 the company had a P/S ratio of 0.3453.
P/S ratio history for Emergent BioSolutions from 2006 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.3453 | -34.3% |
| 2022 | 0.5256 | -59.71% |
| 2021 | 1.30 | -57.27% |
| 2020 | 3.05 | 21.06% |
| 2019 | 2.52 | -34.99% |
| 2018 | 3.88 | -6.16% |
| 2017 | 4.13 | 57.61% |
| 2016 | 2.62 | -13.03% |
| 2015 | 3.02 | 32.21% |
| 2014 | 2.28 | -15.27% |
| 2013 | 2.69 | 31.91% |
| 2012 | 2.04 | -7.84% |
| 2011 | 2.21 | -22.84% |
| 2010 | 2.87 | 60.83% |
| 2009 | 1.78 | -59.21% |
| 2008 | 4.38 | 431.65% |
| 2007 | 0.8230 | -59.19% |
| 2006 | 2.02 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.35 | 1,387.47% | 🇺🇸 USA |
 Merck MRK | 4.59 | 2,806.74% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.18 | 1,279.69% | 🇬🇧 UK |
 Soligenix SNGX | 4.77 | 2,923.83% | 🇺🇸 USA |
 SIGA Technologies SIGA | 3.65 | 2,213.18% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 385 | 243,854.24% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.7872 | 398.90% | 🇮🇱 Israel |